Stock Analiz

Mangoceuticals, Inc. MGRX

Misc Health and Biotechnology Services · IPO 2023 · data as of November 13, 2026

$0.15Market cap $3M
Open the interactive analysis →

Mangoceuticals, Inc. (MGRX) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to June 30, 2026 it had revenue of $315227 and net income of -$16M, a net margin of -5164.4%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -285%.

About Mangoceuticals

Mangoceuticals is listed in the US and classified in misc health and biotechnology services, IPO year 2023. Revenue went from $8939 in 2022 to $456021 in 2025, growth of about 270.9% a year. It was profitable in 0 of the last 4 years in our data. Its share count rose by 1299% over three years (dilution for shareholders).

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S10.9
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-112.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-26.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-7388.0%
ROIC (5-yr avg.)-284.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal yearTTM2025202420232022
Revenue$315227$456021$615873$731493$8939
Net income-$16M-$21M-$9M-$9M-$2M
Free cash flow-$4M——-$7M-$1M
EPS (diluted)$-1.01$-2.17$-4.80$-8.58$-2.85
Net margin-5164.4%-4526.8%-1413.6%-1259.4%-22352.1%
ROIC—-91.9%-44.5%-806.1%-196.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Mangoceuticals pay a dividend?

Not currently.

Is Mangoceuticals a good stock to buy?

We do not give buy or sell advice. Mangoceuticals scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.